TEE
SPRY icon

Tibra Equities Europe’s ARS Pharmaceuticals SPRY Stock Holding History

Tibra Equities Europe’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-12,900
Closed -$598K – 117
2020
Q4 		$598K Buy
+12,900
New +$431K 0.06% 111

Other funds holding SPRY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Tibra Equities Europe's SPRY Position: Q1 2021 in Review

Tibra Equities Europe sold out of ARS Pharmaceuticals (SPRY) in Q1 2021, closing a stake of 12,900 shares — an estimated $598K sold.

Tibra Equities Europe first reported a position in SPRY in Q4 2020 and held it in 1 quarter. The position peaked at $598K in Q4 2020. 68 funds tracked by Wall St. Rank hold SPRY as of Q1 2021.

  • Tibra Equities Europe reported no remaining ARS Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Tibra Equities Europe sold 12,900 ARS Pharmaceuticals shares in Q1 2021, an estimated $598K.
  • Tibra Equities Europe first reported a position in ARS Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Tibra Equities Europe's ARS Pharmaceuticals position peaked at $598K in Q4 2020.
  • 68 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2021.

Based on Tibra Equities Europe's 13F filing for Q1 2021, filed 17 May 2021.